Experimental Therapeutics for the Treatment of Triple Negative Breast Cancer

Dzeyk, Julian; Yadav, Babasaheb D.; Rosengren, Rhonda J.

doi:10.5772/23054

Breast Cancer - Current and Alternative Therapeutic Modalities 2011

DOI: 10.5772/23054

|View full text |Cite

Experimental Therapeutics for the Treatment of Triple Negative Breast Cancer

Julian Dzeyk¹,

Babasaheb D. Yadav²,

Rhonda J. Rosengren³

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2013

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 98 publications

(109 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Curcumin and its derivatives in breast cancer: Current developments and potential for the treatment of drug-resistant cancers

Cridge¹,

Larsen²,

Rosengren³

2013

Oncol Discov

View full text Add to dashboard Cite

Curcumin, a spice found in curry powder, is receiving considerable attention as a possible chemopreventative and chemotherapeutic. This review considers the evidence for the use of curcumin as a treatment for breast cancer, particularly triple negative breast cancers (lacking ER, PR and HER2) which are resistant to many current treatments. Evidence suggests that curcumin suppresses the growth of breast cancers both in vitro and in vivo. In ER-cell lines curcumin causes apoptosis via a range of mechanisms at concentrations ranging between 1 µM and 7.6 µM depending on the cell line and system. In xenograft models, curcumin has been shown to be effective but is limited by its bioavailability. This can be improved by nanotechnologies such as micelles. Studies with micelles have shown that these systems increase the uptake and cytotoxicity of curcumin in vitro. In xenotransplantation models micelles improved bioavailability and increased the half-life of curcumin while showing increases in apoptosis in implanted tumours. The last area discussed is the development of curcumin derivatives. Many of these show increased cytotoxicity (less than 1 µM) and improved pharmacokinetic profiles in vivo. The most potent of these compounds developed to date are RL66 and RL71 with IC 50 values less than 1 µM across a range of breast cancer cell lines, decreased metastasis in a xenograft model, decreased angiogenesis markers and improved tumour growth inhibition as compared to curcumin. Overall, this review concludes that curcumin and its derivatives show future potential as a powerful broad-spectrum treatment for breast cancer.

show abstract

Curcumin and its derivatives in breast cancer: Current developments and potential for the treatment of drug-resistant cancers

Cridge¹,

Larsen²,

Rosengren³

2013

Oncol Discov

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Experimental Therapeutics for the Treatment of Triple Negative Breast Cancer

Cited by 1 publication

References 98 publications

Curcumin and its derivatives in breast cancer: Current developments and potential for the treatment of drug-resistant cancers

Curcumin and its derivatives in breast cancer: Current developments and potential for the treatment of drug-resistant cancers

Contact Info

Product

Resources

About